Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Aegon Ltd. (AEG) vs Eli Lilly And Co (LLY) Price & Performance

Aegon Ltd.Trade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

Aegon Ltd. vs Eli Lilly And Co — how do they compare? Aegon Ltd. trades at $9.41 (market cap $14.01B), while Eli Lilly And Co trades at $1,216 (market cap $1.08T). The key difference: Eli Lilly And Co is far larger — about 77.1× Aegon Ltd.'s market cap, and Aegon Ltd. pays the higher dividend (4.94%). Which is the better fit depends on your goals.

AEGLLY
Market Cap
$14.01B$1.08T
Sector
FinancialsHealth
52-Week High
$9.53$1.24K
52-Week Low
$6.79$639.43
Enterprise Value
$15.16B$1.13T
Dividend Yield
4.94%0.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Aegon Ltd.

AEG trades at $9.41, down 0.48% with a bullish technical signal from moving averages. The company shows improving fundamentals with revenue growth from $19.5B in 2024 to $26.9B in 2025 and net income increasing to $977M. Recent strategic moves include relocating to Delaware and simplifying governance while maintaining a dividend payout. Analyst consensus is mixed with 28% buy ratings but 50% hold recommendations.

AEG presents a turnaround story with improving profitability and strategic refocusing on US markets. Key opportunities include continued earnings growth and potential buybacks, while risks involve execution of the US transition and maintaining momentum amid volatile cash flow patterns. The stock offers value with a P/E of 13.5 and P/S of 0.57.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,221.21, down 0.84% today, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows technical strength with bullish moving averages and support at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 48% revenue growth in Q2 2026. Recent news highlights the company's aggressive protection of its obesity drug pipeline against black market sales.

LLY presents a compelling growth story with dominant market positioning in weight-loss drugs and strong analyst support (73% buy ratings). Key risks include regulatory scrutiny and competitive pressures, but the company's raised guidance and pipeline advancements support continued upside toward the $1,380 consensus target.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Aegon Ltd.

Aegon is a Netherlands-headquartered insurance company with core operations that stretch across the U.S., Netherlands, and United Kingdom. The business also holds peripheral ventures in Spain, Portugal, Brazil, and China.

Read more on AEG

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY